PURPOSE OF REVIEW: Urine is increasingly being investigated as a convenient clinical sample for the identification of mycobacterial products for the diagnosis of tuberculosis. The available literature on mycobacterial lipoarabinomannan (LAM) and urine mycobacterial DNA is reviewed. RECENT FINDINGS: The available data, despite being extracted from heterogeneous clinical populations and different clinical subgroups, indicate that urine LAM has little diagnostic utility in unselected tuberculosis suspects; however, test characteristics improve in HIV-infected patients, particularly those with advanced immunosuppression (CD4 cell count <200 cells/microl). Methodologies for urine PCR for detection of mycobacterial DNA vary across studies and focus is on standardizing assays with respect to specimen collection, assay design, and processing methodology. SUMMARY: Both the urine LAM and PCR for mycobacterial DNA are being evaluated in different geographical settings. Urine LAM currently offers little utility for the diagnosis of tuberculosis in unselected populations. However, urine LAM appears promising as a diagnostic tool in HIV-infected patients with CD4 cell counts less than 200 cells/microl in different clinical settings. Further developmental studies are required to enhance the performance of the assays, and their usefulness over sputum microscopy in HIV-infected patients with advanced immunosuppression requires definition in large cohort studies.
PURPOSE OF REVIEW: Urine is increasingly being investigated as a convenient clinical sample for the identification of mycobacterial products for the diagnosis of tuberculosis. The available literature on mycobacterial lipoarabinomannan (LAM) and urine mycobacterial DNA is reviewed. RECENT FINDINGS: The available data, despite being extracted from heterogeneous clinical populations and different clinical subgroups, indicate that urine LAM has little diagnostic utility in unselected tuberculosis suspects; however, test characteristics improve in HIV-infectedpatients, particularly those with advanced immunosuppression (CD4 cell count <200 cells/microl). Methodologies for urine PCR for detection of mycobacterial DNA vary across studies and focus is on standardizing assays with respect to specimen collection, assay design, and processing methodology. SUMMARY: Both the urine LAM and PCR for mycobacterial DNA are being evaluated in different geographical settings. Urine LAM currently offers little utility for the diagnosis of tuberculosis in unselected populations. However, urine LAM appears promising as a diagnostic tool in HIV-infectedpatients with CD4 cell counts less than 200 cells/microl in different clinical settings. Further developmental studies are required to enhance the performance of the assays, and their usefulness over sputum microscopy in HIV-infectedpatients with advanced immunosuppression requires definition in large cohort studies.
Authors: L A Sechi; M P Pinna; A Sanna; P Pirina; F Ginesu; F Saba; A Aceti; F Turrini; S Zanetti; G Fadda Journal: Mol Cell Probes Date: 1997-08 Impact factor: 2.365
Authors: Keertan Dheda; Virginia Davids; Laura Lenders; Teri Roberts; Richard Meldau; Daphne Ling; Laurence Brunet; Richard van Zyl Smit; Jonathan Peter; Clare Green; Motasim Badri; Leonardo Sechi; Surendra Sharma; Michael Hoelscher; Rodney Dawson; Andrew Whitelaw; Jonathan Blackburn; Madhukar Pai; Alimuddin Zumla Journal: PLoS One Date: 2010-03-24 Impact factor: 3.240
Authors: Stephen D Lawn; David J Edwards; Katharina Kranzer; Monica Vogt; Linda-Gail Bekker; Robin Wood Journal: AIDS Date: 2009-09-10 Impact factor: 4.177
Authors: Natalie J Garton; Simon J Waddell; Anna L Sherratt; Su-Min Lee; Rebecca J Smith; Claire Senner; Jason Hinds; Kumar Rajakumar; Richard A Adegbola; Gurdyal S Besra; Philip D Butcher; Michael R Barer Journal: PLoS Med Date: 2008-04-01 Impact factor: 11.069
Authors: Maunank Shah; Neil A Martinson; Richard E Chaisson; Desmond J Martin; Ebrahim Variava; Susan E Dorman Journal: J Clin Microbiol Date: 2010-06-09 Impact factor: 5.948
Authors: Jonathan G Peter; Grant Theron; Richard van Zyl-Smit; Asheen Haripersad; Lynelle Mottay; Sarah Kraus; Anke Binder; Richard Meldau; Anneli Hardy; Keertan Dheda Journal: Eur Respir J Date: 2012-02-23 Impact factor: 16.671
Authors: Hali Bordelon; Keersten M Ricks; Megan E Pask; Patricia K Russ; Francesca Solinas; Mark L Baglia; Philip A Short; Andrew Nel; Jonathan Blackburn; Keertan Dheda; Carlos Zamudio; Tatiana Cáceres; David W Wright; Frederick R Haselton; April C Pettit Journal: J Microbiol Methods Date: 2017-03-09 Impact factor: 2.363
Authors: Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart Journal: Cochrane Database Syst Rev Date: 2018-08-27